“Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025” Report highlight:
- Diabetes Drug Market Opportunity: > US$ 1.5 Billion by 2025
- Diabetes Device Market Opportunity: > US$ 1 Billion by 2025
- Glucose Monitoring Device Market Absolute Growth: 33% (2019-2025)
- Oral Hypoglycemic Drugs Market – Availability, Dosage & Price Analysis
- Insulin Availability, Dosage & Price Analysis
- Insulin Delivery Device Market – Availability, Price & Sales Analysis
- Glucose Monitoring Device Market – Availability & Price Analysis
- Investments & Collaborations by Leading Market Players
Download Report: https://www.kuickresearch.com/report-saudi-arabia-diabetes-drug-insulin-delivery-device-market-size-sales
Table of Contents
- Introduction to Saudi Arabia Diabetes Market
1.1 Overview
1.2 Current Market Scenario
- Saudi Arabia – Diabetes Prevalence & Statistics
2.1 By Population
2.2 By Diabetes Type
2.2.1 Type 1 Diabetes
2.2.2 Type 2 Diabetes
2.3 By Age & Gender
2.4 Obesity & Overweight
- Saudi Arabia – Pharmaceutical Pricing & Reimbursement Policies
3.1 Pricing Policies
3.1.1 In-Patent Pharmaceuticals
3.1.2 Off-Patent, Generics & Other Locally Manufactured Product
3.2 Procurement & Reimbursement Policies
- Saudi Arabia – Regulatory Aspects of Pharmaceutical Products
4.1 Gulf Central Committee for Drug Registrations (GCC-DR)
4.2 Regulatory Review Process
4.3 Centralized Registration
4.4 Decentralized Drug Registration Regulation
- Saudi Arabia – Diabetes Drug Market
5.1 Market Analysis
5.2 Prescription Pattern
- Saudi Arabia – Oral Hypoglycemic Drugs Market – Availability, Dosage & Price Analysis
6.1 Biguanides (Metformin Hydrochloride)
6.1.1 Glucophage
6.1.2 Glucare XR
6.1.3 Dimetor
6.1.4 Formit XR
6.2 Sulfonylurea
6.2.1 Gliclazide
6.2.2 Glimepiride
6.2.3 Glibenclamide
6.3 DPP-4 Inhibitors
6.3.1 Vildagliptin
6.3.2 Saxagliptin (Onglyza)
6.3.3 Sitagliptin (Januvia)
6.4 SGLT2 Inhibitors
6.4.1 Canagliflozin (Invokana)
6.4.2 Dapagliflozin (Forxiga)
6.4.3 Empagliflozin (Jardiance)
6.5 Others
6.5.1 Meglitinides
6.5.2 Thiazolidinediones
6.5.3 α-Glucosidase Inhibitors
6.6 Combinational Drugs
6.6.1 Metformin & Sulfonylurea Combination
6.6.2 Metformin & DPP-4 Inhibitors Combination
6.6.3 Metformin & SGLT-2 Inhibitors Combination
- Saudi Arabia Insulin Market – Availability, Dosage & Price Analysis
7.1 Lantus
7.2 Humulin
7.2.1 Humulin 70/30 100U/ml
7.2.2 Humulin N-NPH
7.3 Humalog
7.4 Mixtard
7.5 Apidra
7.6 Insulatard
- Saudi Arabia – Diabetes Device Market Analysis
- Saudi Arabia Insulin Delivery Device Market – Availability, Price & Sales Analysis
9.1 Insulin Syringes
9.2 Insulin Pen
9.2.1 Humalog KwikPen
9.2.2 Flexpen
9.2.3 Solostar
9.2.4 NovoPen
9.2.5 Others
9.3 Insulin Pumps
9.4 Insulin Jet Injectors
- Saudi Arabia – Glucose Monitoring Device Market – Availability & Price Analysis
10.1 Self-Monitoring Blood Glucose Devices
10.2 Continuous Glucose Monitoring Device
- Saudi Arabia Diabetes Market – Clinical Insight
- Saudi Arabia Diabetes Market – Investments & Collaborations by Leading MNCs
- Saudi Arabia Diabetes Market Dynamics
13.1 Market Drivers
13.2 Challenges for Saudi Arabia Diabetes Market
- Saudi Arabia Diabetes Drug Market Future Outlook
- Competitive Landscape
15.1 Abbott
15.2 Aljazeera Pharmaceutical Industries
15.3 Al Mojil Drug Company
15.4 AstraZeneca
15.5 Bayer
15.6 CAD Middle-East Pharmaceutical Company
15.7 Eli – Lilly
15.8 Julphur Pharmaceuticals
15.9 Kuwait Saudi Pharmaceutical Company
15.10 Merck
15.11 Novartis
15.12 Oman Pharmaceuticals
15.13 Roche
15.14 Saja Pharmaceuticals
15.15 Sanofi
15.16 Servier
15.17 SPIMACO Addwaeih
15.18 Tabuk Pharmaceuticals
15.19 Qatar Life Pharma
15.20 YIACO Medical Company
Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-09810410366
